DSM-Firmenich rises after it agrees to divest feed enzymes venture

Novozymes A/S

11/02/2025 08:31

** Amsterdam-listed shares in DSM-Firmenich  DSFIR.AS  gain
as much as 5.5% after the Swiss-Dutch chemical manufacturer has
agreed to sell its stake in a joint enzymes venture to partner
Novonesis for 1.5 billion euros ($1.55 billion)
    ** The move comes as says DSM says it seeks options to exit
its animal nutrition and health business 
    ** KBC Securities sees it as a good deal which puts DSM
"well into a net cash territory," allowing the company to
strengthen its consumer-oriented activities 
    ** At 0815 GMT the stock is up 3.5% to EUR 99.32

($1 = 0.9704 euros)

 (Reporting by Jakob Van Calster)
 ((Jakob.vancalster@thomsonreuters.com))